麝香保心丸治疗急性非ST段抬高型心肌梗死临床研究  

Clinical Study on the Treatment of Acute Non ST Segment Elevation Myocardial Infarction with Shexiang Baoxin Pill

作　　者：杨国亮[1] 宋会新 刘建辉[1] 李海妍[1] 刘平 曹鑫明 

机构地区：[1]秦皇岛市北戴河医院,河北秦皇岛066100

出　　处：《河南中医》2013年第11期1886-1888,共3页Henan Traditional Chinese Medicine

摘　　要：目的:观察应用麝香保心丸治疗急性非ST段抬高型心肌梗死(NSTEMI)患者的临床疗效。方法:选择120例NSTEMI患者,随机分为治疗组及对照组各60例,两组均给予常规治疗,治疗组加用麝香保心丸口服,2丸/次,3次/d,24周为1个疗程,比较两组患者心血管事件发生率(梗死后心绞痛的发生率、非致死性再梗死率、心源性休克的发生率、心因性死亡率)以及治疗前后左室射血分数(LVEF)、钠尿肽(BNP)的变化情况。结果:治疗组梗死后心绞痛的发生率、非致死性再梗死率、心源性休克的发生率、心因性死亡率与对照组比较有统计学意义(P<0.05),LVEF及BNP的改善均优于对照组(P<0.05)。结论:麝香保心丸治疗急性非ST段抬高型心肌梗死,不仅可以减少NSTEMI患者心血管事件的发生,而且可以改善左心功能。Objective: To observe the effects of Shexiang Baoxin Pill on acute non ST segment elevation myocardial infarction( NSTEMI). Methods: 120 cases of NSTEMI patients were randomly divided into treatment group and control group,with 60 cases in each group. Both groups were given conventional treatment,and the treatment group was given additional treatment of Shexiang Baoxin Pill,2 pills once,3 times / d,24 weeks for 1 course of treatment. Compared the incidence rates of cardiovascular events of two groups( the incidence rate of postinfarction angina,non fatal reinfarction rate,the incidence rate of cardiogenic shock,cardiogenic mortality rate) and the changes of left ventricular rejection fraction( LVEF) and brain natriuretic peptide( BNP). Results: Compared with those of the control group,the incidence rate of postinfarction angina,non fatal reinfarction rate,the incidence rate of cardiogenic shock and cardiogenic mortality rate in the treatment group were statistically significant( P <0. 05),LVEF and BNP were better than those of the control group( P <0. 05). Conclusion: Shexiang Baoxin Pill in the treatment of acute NSTEMI not only can reduce the occurrence of cardiovascular events in NSTEMI patients,but improve the left ventricular function.

关 键 词：麝香保心丸 急性非ST段抬高型心肌梗死 心血管事件 左心功能 

分 类 号：R542.22[医药卫生—心血管疾病]